Indivior (INDV) Q2 2025 Earnings Call July 31, 2025 08:00 AM ET Company ParticipantsJason Thompson - VP - IRJoe Ciaffoni - CEO & DirectorPatrick Barry - Chief Commercial OfficerRyan Preblick - CFO & Executive DirectorThibault Boutherin - Executive Director - Equity ResearchConference Call ParticipantsDavid Amsellem - Senior Research AnalystChase Knickerbocker - Senior Equity Research Analyst - HealthcareDennis Ding - VP - Equity Research AnalystCarl Byrnes - MD - Senior Research AnalystOperatorGood day, and ...

Agios Pharmaceuticals (AGIO) Q2 2025 Earnings Call July 31, 2025 08:00 AM ET Speaker0Good morning and welcome to Agio's Second Quarter twenty twenty five Conference Call. At this time, all participants are in a listen only mode. There will be a question and answer session at the end. Please be advised that this call is being recorded at Agio's request. I would now like to turn the call over to Agio.Please go ahead.Speaker1Thank you, operator. Good morning, everyone. I'm Morgan Sanford, Vice President of Inv ...

Indivior (INDV) Q2 2025 Earnings Call July 31, 2025 08:00 AM ET Speaker0Good day, and thank you for standing by. Welcome to the Indivia Second Quarter twenty twenty five Results Conference Call and Webcast. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please note that today's conference is being recorded.I would now like to hand the conference over to Jason Thompson, your host for today's call. Please go ahead.Speake ...

COMPASS Pathways (CMPS) Q2 2025 Earnings Call July 31, 2025 08:00 AM ET Speaker0Hello, everyone, and welcome to Compass Pathways Second Quarter twenty twenty five Earnings Conference Call. Please note that this call is being recorded. After the speakers' prepared remarks, there will be a question and answer session. Thank you. I'd now like to hand the call over to Stephen Schultz, Senior Vice President of Investor Relations.You may now go ahead, please.Speaker1Welcome all of you, and thank you for joining u ...

Business Finance Pipeline Appendices Business Finance Pipeline Appendices Results Q2 2025 July 31, 2025 Abbreviations used in the main presentation are defined in the list of abbreviations. In the appendices, abbreviations are written in full the first time used. 3 Investor Relations Business Finance Pipeline Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are st ...

Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call July 31, 2025 08:00 AM ET Speaker0Good day, and welcome to the Bristol Myers Squibb Second Quarter twenty twenty five Earnings Conference Call. All participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Mr.Chuck Triano, Senior Vice President and Head of Investor Relations. Please go ahead, sir.Speake ...

Vanda Pharmaceuticals (VNDA) Q2 2025 Earnings Call July 31, 2025 08:00 AM ET Speaker0Good day, everyone, and thank you for standing by. My name is Argy, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q2 twenty twenty five Vanda Pharmaceuticals Inc. Earnings Conference Call. All lines have been placed on mute to prevent any background noise.After the speakers' remarks, there will be a question and answer session. Thank you. I would now like to turn the cal ...

NEW YORK, July 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN).Shareholders who purchased shares of BHVN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/biohaven-ltd-loss-submission-form/?id=158795&from=4 CLASS PERIOD: March 24, 2023 to May 14, 2 ...

Reaching Patients Through Immunology Innovation This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. 2Q 202 5 FINANCIAL RESULTS CALL JULY 31, 202 5 Forward Looking Statements This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representat ...

Strategic CRO Partnership Supports Operational Readiness and Initiation of Upcoming Concussion StudySARASOTA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological conditions, today announced the selection of Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase IIa clinical trial of ONP-002, the company’s lead drug candidate for concussion. Southern Star R ...